why choose us

First received: July 26, 2022

Clinical Trial: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Platinum-resistant Ovarian Cancer

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Phase 1b Study of SL-172154 (SIRP?-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

Brief Summary: SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer.Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.

Read more